Zobrazeno 1 - 10
of 155
pro vyhledávání: '"Maxwell Sehested"'
Autor:
Michael Jeffers, Henri S. Lichenstein, Maxwell Sehested, Annemette Thougaard, Kamille Dumong Petersen, Frank Wu, Gulshan Ara, William J. LaRochelle, Xiaozhong Qian
Supplemental Table S2 from Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40168a14b344b02e05f1362451352fda
https://doi.org/10.1158/1535-7163.22484604.v1
https://doi.org/10.1158/1535-7163.22484604.v1
Data from Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies
Autor:
Michael Jeffers, Henri S. Lichenstein, Maxwell Sehested, Annemette Thougaard, Kamille Dumong Petersen, Frank Wu, Gulshan Ara, William J. LaRochelle, Xiaozhong Qian
Histone deacetylase inhibitors represent a promising new class of anticancer agents. In the current investigation, we examined the activity of PXD101, a potent histone deacetylase inhibitor, used alone or in combination with clinically relevant chemo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c0c4d95e56c2198a6e958a16e2a4799
https://doi.org/10.1158/1535-7163.c.6531480
https://doi.org/10.1158/1535-7163.c.6531480
Supplementary Figure 2 from Retinoblastoma Pathway Defects Show Differential Ability to Activate the Constitutive DNA Damage Response in Human Tumorigenesis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a467068587b1aafce0a553d1d80ba5d0
https://doi.org/10.1158/0008-5472.22366514
https://doi.org/10.1158/0008-5472.22366514
Supplementary Figure Legends 1-4 from Retinoblastoma Pathway Defects Show Differential Ability to Activate the Constitutive DNA Damage Response in Human Tumorigenesis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76fa04bc5b85436c16c255b25987b8c1
https://doi.org/10.1158/0008-5472.22366505
https://doi.org/10.1158/0008-5472.22366505
Supplementary Figure 1 from Retinoblastoma Pathway Defects Show Differential Ability to Activate the Constitutive DNA Damage Response in Human Tumorigenesis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bb67dd68eea2b407c326e2e0092f4a7
https://doi.org/10.1158/0008-5472.22366517.v1
https://doi.org/10.1158/0008-5472.22366517.v1
Loss of G1-S control and aberrations of the p16Ink4a-cyclin D1/cyclin-dependent kinase (CDK) 4(6)-pRb-E2F-cyclin E/CDK2 pathway are common in human cancer. Previous studies showed that oncogene-induced aberrant proliferation, such as on cyclin E over
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f60f5ad06bbba9b421acad23b00b522
https://doi.org/10.1158/0008-5472.c.6495170.v1
https://doi.org/10.1158/0008-5472.c.6495170.v1
Supplementary Figure 3 from Retinoblastoma Pathway Defects Show Differential Ability to Activate the Constitutive DNA Damage Response in Human Tumorigenesis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::604b09c14ee39f8eed435af287d28c7d
https://doi.org/10.1158/0008-5472.22366511
https://doi.org/10.1158/0008-5472.22366511
Supplementary Figure 4 from Retinoblastoma Pathway Defects Show Differential Ability to Activate the Constitutive DNA Damage Response in Human Tumorigenesis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40d9f9022a1d5ce7c762d8b710027dff
https://doi.org/10.1158/0008-5472.22366508.v1
https://doi.org/10.1158/0008-5472.22366508.v1
Autor:
Mette Munk Jensen, Kamille Dumong Erichsen, Camilla Bardram Johnbeck, Fredrik Björkling, Jacob Madsen, Michael Bzorek, Peter Buhl Jensen, Liselotte Højgaard, Maxwell Sehested, Andreas Kjær
Publikováno v:
PLoS ONE, Vol 8, Iss 1, p e53410 (2013)
INTRODUCTION: APO866 is a new anti-tumor compound inhibiting nicotinamide phosphoribosyltransferase (NAMPT). APO866 has an anti-tumor effect in several pre-clinical tumor models and is currently in several clinical phase II studies. 3'-deoxy-3'-[18F]
Externí odkaz:
https://doaj.org/article/4f5b82668a2e4f9fb9d19b9b6872e7fc
Autor:
Mette Munk Jensen, Kamille Dumong Erichsen, Fredrik Björkling, Jacob Madsen, Peter Buhl Jensen, Maxwell Sehested, Liselotte Højgaard, Andreas Kjær
Publikováno v:
PLoS ONE, Vol 8, Iss 12, p e85126 (2013)
A combination of carboplatin and paclitaxel is often used as first line chemotherapy for treatment of ovarian cancer. Therefore the use of imaging biomarkers early after initiation of treatment to determine treatment sensitivity would be valuable in
Externí odkaz:
https://doaj.org/article/5fd62e64e3c7405580c91ff66d54d660